Trial Profile
A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Pleconaril (Primary) ; Ribavirin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Apodemus
- 04 Sep 2016 Status changed from recruiting to discontinued.
- 06 Oct 2014 New trial record